BIB holdings
ProShares Ultra Nasdaq Biotechnology
Positions
267 stored of 267 reported, largest first by weight
| # | Holding | ISIN | CUSIP | Weight | Value (USD) | Type | Issuer type | Country | Currency |
|---|---|---|---|---|---|---|---|---|---|
| 101 | Ultragenyx Pharmaceutical, Inc. | US90400D1081 | 90400D108 | 0.116% | $85K | Equity (common) | Corporate | United States | USD |
| 102 | Legend Biotech Corp. | US52490G1022 | 52490G102 | 0.115% | $85K | Equity (common) | Corporate | Cayman Islands | USD |
| 103 | Kodiak Sciences, Inc. | US50015M1099 | 50015M109 | 0.112% | $83K | Equity (common) | Corporate | United States | USD |
| 104 | BioCryst Pharmaceuticals, Inc. | US09058V1035 | 09058V103 | 0.112% | $83K | Equity (common) | Corporate | United States | USD |
| 105 | Kiniksa Pharmaceuticals International plc Kiniksa Pharmaceuticals International plc, Class A | GB00BRXB0C07 | Not reported | 0.112% | $82K | Equity (common) | Corporate | United Kingdom | USD |
| 106 | Aurinia Pharmaceuticals, Inc. | CA05156V1022 | 05156V102 | 0.102% | $75K | Equity (common) | Corporate | Canada | USD |
| 107 | Ocular Therapeutix, Inc. | US67576A1007 | 67576A100 | 0.098% | $73K | Equity (common) | Corporate | United States | USD |
| 108 | Novocure Ltd. | JE00BYSS4X48 | Not reported | 0.097% | $72K | Equity (common) | Corporate | Jersey | USD |
| 109 | Pharvaris NV | NL00150005Y4 | Not reported | 0.097% | $71K | Equity (common) | Corporate | Netherlands | USD |
| 110 | Sionna Therapeutics, Inc. | US8294011080 | 829401108 | 0.096% | $71K | Equity (common) | Corporate | United States | USD |
| 111 | ADMA Biologics, Inc. | US0008991046 | 000899104 | 0.095% | $70K | Equity (common) | Corporate | United States | USD |
| 112 | Rapport Therapeutics, Inc. | US75383L1026 | 75383L102 | 0.095% | $70K | Equity (common) | Corporate | United States | USD |
| 113 | Zymeworks, Inc. | US98985Y1082 | 98985Y108 | 0.094% | $70K | Equity (common) | Corporate | United States | USD |
| 114 | Recursion Pharmaceuticals, Inc. Recursion Pharmaceuticals, Inc., Class A | US75629V1044 | 75629V104 | 0.094% | $69K | Equity (common) | Corporate | United States | USD |
| 115 | Sarepta Therapeutics, Inc. | US8036071004 | 803607100 | 0.094% | $69K | Equity (common) | Corporate | United States | USD |
| 116 | AbCellera Biologics, Inc. | CA00288U1066 | 00288U106 | 0.094% | $69K | Equity (common) | Corporate | Canada | USD |
| 117 | Harmony Biosciences Holdings, Inc. | US4131971040 | 413197104 | 0.092% | $68K | Equity (common) | Corporate | United States | USD |
| 118 | Nurix Therapeutics, Inc. | US67080M1036 | 67080M103 | 0.092% | $68K | Equity (common) | Corporate | United States | USD |
| 119 | Trevi Therapeutics, Inc. | US89532M1018 | 89532M101 | 0.091% | $67K | Equity (common) | Corporate | United States | USD |
| 120 | Novavax, Inc. | US6700024010 | 670002401 | 0.090% | $66K | Equity (common) | Corporate | United States | USD |
| 121 | Tyra Biosciences, Inc. | US90240B1061 | 90240B106 | 0.090% | $66K | Equity (common) | Corporate | United States | USD |
| 122 | uniQure NV | NL0010696654 | Not reported | 0.089% | $66K | Equity (common) | Corporate | Netherlands | USD |
| 123 | Stoke Therapeutics, Inc. | US86150R1077 | 86150R107 | 0.089% | $65K | Equity (common) | Corporate | United States | USD |
| 124 | ANI Pharmaceuticals, Inc. | US00182C1036 | 00182C103 | 0.088% | $65K | Equity (common) | Corporate | United States | USD |
| 125 | Syndax Pharmaceuticals, Inc. | US87164F1057 | 87164F105 | 0.087% | $64K | Equity (common) | Corporate | United States | USD |
| 126 | Agios Pharmaceuticals, Inc. | US00847X1046 | 00847X104 | 0.086% | $64K | Equity (common) | Corporate | United States | USD |
| 127 | Genmab A/S | US3723032062 | 372303206 | 0.085% | $63K | Equity (common) | Corporate | Denmark | USD |
| 128 | Vericel Corp. | US92346J1088 | 92346J108 | 0.085% | $62K | Equity (common) | Corporate | United States | USD |
| 129 | Iovance Biotherapeutics, Inc. | US4622601007 | 462260100 | 0.085% | $62K | Equity (common) | Corporate | United States | USD |
| 130 | Intellia Therapeutics, Inc. | US45826J1051 | 45826J105 | 0.083% | $61K | Equity (common) | Corporate | United States | USD |
| 131 | AtaiBeckley, Inc. | US04650F1012 | 04650F101 | 0.083% | $61K | Equity (common) | Corporate | United States | USD |
| 132 | Taysha Gene Therapies, Inc. | US8776191061 | 877619106 | 0.081% | $59K | Equity (common) | Corporate | United States | USD |
| 133 | Innoviva, Inc. | US45781M1018 | 45781M101 | 0.080% | $59K | Equity (common) | Corporate | United States | USD |
| 134 | Amylyx Pharmaceuticals, Inc. | US03237H1014 | 03237H101 | 0.079% | $58K | Equity (common) | Corporate | United States | USD |
| 135 | AnaptysBio, Inc. | US0327241065 | 032724106 | 0.077% | $57K | Equity (common) | Corporate | United States | USD |
| 136 | Precigen, Inc. | US74017N1054 | 74017N105 | 0.077% | $57K | Equity (common) | Corporate | United States | USD |
| 137 | Inhibrx Biosciences, Inc. | US45720N1037 | 45720N103 | 0.076% | $56K | Equity (common) | Corporate | United States | USD |
| 138 | Monte Rosa Therapeutics, Inc. | US61225M1027 | 61225M102 | 0.075% | $56K | Equity (common) | Corporate | United States | USD |
| 139 | Vir Biotechnology, Inc. | US92764N1028 | 92764N102 | 0.075% | $55K | Equity (common) | Corporate | United States | USD |
| 140 | GH Research plc | IE000GID8VI0 | Not reported | 0.075% | $55K | Equity (common) | Corporate | Ireland | USD |
| 141 | Ardelyx, Inc. | US0396971071 | 039697107 | 0.074% | $55K | Equity (common) | Corporate | United States | USD |
| 142 | Fortrea Holdings, Inc. | US34965K1079 | 34965K107 | 0.072% | $53K | Equity (common) | Corporate | United States | USD |
| 143 | MBX Biosciences, Inc. | US55287L1017 | 55287L101 | 0.071% | $52K | Equity (common) | Corporate | United States | USD |
| 144 | Bicara Therapeutics, Inc. | US0554771032 | 055477103 | 0.069% | $51K | Equity (common) | Corporate | United States | USD |
| 145 | KalVista Pharmaceuticals, Inc. | US4834971032 | 483497103 | 0.068% | $50K | Equity (common) | Corporate | United States | USD |
| 146 | Septerna, Inc. | US81734D1046 | 81734D104 | 0.068% | $50K | Equity (common) | Corporate | United States | USD |
| 147 | UroGen Pharma Ltd. | IL0011407140 | Not reported | 0.066% | $49K | Equity (common) | Corporate | Israel | USD |
| 148 | Harrow, Inc. | US4158581094 | 415858109 | 0.065% | $48K | Equity (common) | Corporate | United States | USD |
| 149 | Maze Therapeutics, Inc. | US5787841007 | 578784100 | 0.064% | $47K | Equity (common) | Corporate | United States | USD |
| 150 | Immunocore Holdings plc | US45258D1054 | 45258D105 | 0.064% | $47K | Equity (common) | Corporate | United Kingdom | USD |
| 151 | ArriVent Biopharma, Inc. | US04272N1028 | 04272N102 | 0.063% | $46K | Equity (common) | Corporate | United States | USD |
| 152 | WaVe Life Sciences Ltd. | SG9999014716 | Not reported | 0.062% | $46K | Equity (common) | Corporate | Singapore | USD |
| 153 | Compass Pathways plc | US20451W1018 | 20451W101 | 0.062% | $46K | Equity (common) | Corporate | United Kingdom | USD |
| 154 | Personalis, Inc. | US71535D1063 | 71535D106 | 0.060% | $44K | Equity (common) | Corporate | United States | USD |
| 155 | MannKind Corp. | US56400P7069 | 56400P706 | 0.058% | $43K | Equity (common) | Corporate | United States | USD |
| 156 | EyePoint, Inc. | US30233G2093 | 30233G209 | 0.056% | $42K | Equity (common) | Corporate | United States | USD |
| 157 | Alvotech SA | LU2458332611 | Not reported | 0.056% | $41K | Equity (common) | Corporate | Luxembourg | USD |
| 158 | Collegium Pharmaceutical, Inc. | US19459J1043 | 19459J104 | 0.053% | $39K | Equity (common) | Corporate | United States | USD |
| 159 | Savara, Inc. | US8051111016 | 805111101 | 0.053% | $39K | Equity (common) | Corporate | United States | USD |
| 160 | Olema Pharmaceuticals, Inc. | US68062P1066 | 68062P106 | 0.053% | $39K | Equity (common) | Corporate | United States | USD |
| 161 | Corvus Pharmaceuticals, Inc. | US2210151005 | 221015100 | 0.051% | $38K | Equity (common) | Corporate | United States | USD |
| 162 | Xeris Biopharma Holdings, Inc. | US98422E1038 | 98422E103 | 0.051% | $38K | Equity (common) | Corporate | United States | USD |
| 163 | Absci Corp. | US00091E1091 | 00091E109 | 0.051% | $38K | Equity (common) | Corporate | United States | USD |
| 164 | Zenas Biopharma, Inc. | US98937L1052 | 98937L105 | 0.050% | $36K | Equity (common) | Corporate | United States | USD |
| 165 | Cullinan Therapeutics, Inc. | US2300311063 | 230031106 | 0.049% | $36K | Equity (common) | Corporate | United States | USD |
| 166 | Grifols SA | US3984384087 | 398438408 | 0.048% | $35K | Equity (common) | Corporate | Spain | USD |
| 167 | Pacira BioSciences, Inc. | US6951271005 | 695127100 | 0.047% | $35K | Equity (common) | Corporate | United States | USD |
| 168 | ARS Pharmaceuticals, Inc. | US82835W1080 | 82835W108 | 0.045% | $33K | Equity (common) | Corporate | United States | USD |
| 169 | Janux Therapeutics, Inc. | US47103J1051 | 47103J105 | 0.045% | $33K | Equity (common) | Corporate | United States | USD |
| 170 | Kura Oncology, Inc. | US50127T1097 | 50127T109 | 0.045% | $33K | Equity (common) | Corporate | United States | USD |
| 171 | Sana Biotechnology, Inc. | US7995661045 | 799566104 | 0.044% | $33K | Equity (common) | Corporate | United States | USD |
| 172 | Arbutus Biopharma Corp. | CA03879J1003 | 03879J100 | 0.044% | $32K | Equity (common) | Corporate | Canada | USD |
| 173 | Xencor, Inc. | US98401F1057 | 98401F105 | 0.044% | $32K | Equity (common) | Corporate | United States | USD |
| 174 | MeiraGTx Holdings plc | KYG596651029 | Not reported | 0.043% | $32K | Equity (common) | Corporate | Cayman Islands | USD |
| 175 | Amphastar Pharmaceuticals, Inc. | US03209R1032 | 03209R103 | 0.043% | $32K | Equity (common) | Corporate | United States | USD |
| 176 | ORIC Pharmaceuticals, Inc. | US68622P1093 | 68622P109 | 0.043% | $31K | Equity (common) | Corporate | United States | USD |
| 177 | Eton Pharmaceuticals, Inc. | US29772L1089 | 29772L108 | 0.041% | $30K | Equity (common) | Corporate | United States | USD |
| 178 | Theravance Biopharma, Inc. | KYG8807B1068 | Not reported | 0.041% | $30K | Equity (common) | Corporate | Cayman Islands | USD |
| 179 | Mesoblast Ltd. | US5907174016 | 590717401 | 0.040% | $30K | Equity (common) | Corporate | Australia | USD |
| 180 | Geron Corp. | US3741631036 | 374163103 | 0.040% | $30K | Equity (common) | Corporate | United States | USD |
| 181 | Annexon, Inc. | US03589W1027 | 03589W102 | 0.039% | $29K | Equity (common) | Corporate | United States | USD |
| 182 | Omeros Corp. | US6821431029 | 682143102 | 0.039% | $29K | Equity (common) | Corporate | United States | USD |
| 183 | Phathom Pharmaceuticals, Inc. | US71722W1071 | 71722W107 | 0.038% | $28K | Equity (common) | Corporate | United States | USD |
| 184 | BioAge Labs, Inc. | US09077V1008 | 09077V100 | 0.038% | $28K | Equity (common) | Corporate | United States | USD |
| 185 | Esperion Therapeutics, Inc. | US29664W1053 | 29664W105 | 0.038% | $28K | Equity (common) | Corporate | United States | USD |
| 186 | Replimune Group, Inc. | US76029N1063 | 76029N106 | 0.036% | $27K | Equity (common) | Corporate | United States | USD |
| 187 | Maravai LifeSciences Holdings, Inc. Maravai LifeSciences Holdings, Inc., Class A | US56600D1072 | 56600D107 | 0.035% | $26K | Equity (common) | Corporate | United States | USD |
| 188 | CorMedix, Inc. | US21900C3088 | 21900C308 | 0.033% | $25K | Equity (common) | Corporate | United States | USD |
| 189 | Zevra Therapeutics, Inc. | US4884452065 | 488445206 | 0.033% | $24K | Equity (common) | Corporate | United States | USD |
| 190 | Prime Medicine, Inc. | US74168J1016 | 74168J101 | 0.032% | $24K | Equity (common) | Corporate | United States | USD |
| 191 | Phibro Animal Health Corp. Phibro Animal Health Corp., Class A | US71742Q1067 | 71742Q106 | 0.032% | $23K | Equity (common) | Corporate | United States | USD |
| 192 | Castle Biosciences, Inc. | US14843C1053 | 14843C105 | 0.031% | $23K | Equity (common) | Corporate | United States | USD |
| 193 | Vor BioPharma, Inc. | US9290332074 | 929033207 | 0.031% | $23K | Equity (common) | Corporate | United States | USD |
| 194 | CytomX Therapeutics, Inc. | US23284F1057 | 23284F105 | 0.031% | $23K | Equity (common) | Corporate | United States | USD |
| 195 | Candel Therapeutics, Inc. | US1374041093 | 137404109 | 0.031% | $22K | Equity (common) | Corporate | United States | USD |
| 196 | Zai Lab Ltd. | US98887Q1040 | 98887Q104 | 0.030% | $22K | Equity (common) | Corporate | Cayman Islands | USD |
| 197 | Design Therapeutics, Inc. | US25056L1035 | 25056L103 | 0.030% | $22K | Equity (common) | Corporate | United States | USD |
| 198 | Tectonic Therapeutic, Inc. | US8789721086 | 878972108 | 0.029% | $22K | Equity (common) | Corporate | United States | USD |
| 199 | Ironwood Pharmaceuticals, Inc. Ironwood Pharmaceuticals, Inc., Class A | US46333X1081 | 46333X108 | 0.029% | $22K | Equity (common) | Corporate | United States | USD |
| 200 | Arvinas, Inc. | US04335A1051 | 04335A105 | 0.029% | $21K | Equity (common) | Corporate | United States | USD |